

EudraCT Number 2014-001081-99

Study title A clinical trial to document safety and radiological disease activity in patients with relapsing-remitting multiple sclerosis treated with autologous CD4+ cells, stimulated and expanded ex vivo by a myelin oligodendrocyte glycoprotein (MOG) peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope (SCLEROLYM trial). First-in-human trial

Sponsor ImCyse

This clinical trial has been prematurely ended; no subjects have been recruited; therefore no clinical results are available.